FindTrial
Sign In

CC-115

DRUG3 trials

Sponsors

Celgene, Memorial Sloan Kettering Cancer Center, David Reardon, MD

Conditions

Castration Resistant Prostate CancerChronic Lymphocytic LeukemiaEwing's OsteosarcomaGlioblastomaGlioblastoma MultiformeNeoplasm MetastasisProstate CancerSquamous Cell Carcinoma of Head and Neck

Phase 1

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
CompletedNCT01353625
CelgeneChronic Lymphocytic Leukemia, Ewing's Osteosarcoma, Glioblastoma Multiforme +3
Start: 2011-04-25End: 2021-03-12Updated: 2021-10-05
Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer
CompletedNCT02833883
Memorial Sloan Kettering Cancer CenterCastration Resistant Prostate Cancer, Prostate Cancer
Start: 2016-07-31End: 2023-01-13Updated: 2023-01-19

Phase 2

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
RecruitingNCT02977780
David Reardon, MDGlioblastoma
Start: 2017-02-09End: 2028-04-30Target: 460Updated: 2026-08-19

Related Papers

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data
Journal of Clinical Oncology2026-05-22
CTNI-73. LAT1 EXPRESSION SCALE AND ADAPTIVE DESIGN FOR A PHASE IIA TRIAL OF QBS72S IN BREAST CANCER BRAIN METASTASES
Neuro-Oncology2025-11-01
Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases
BMC Cancer2025-08-151 citations
CTNI-60. SAFETY LEAD-IN RESULTS FOR QBS10072S IN THE INDIVIDUAL SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT) TRIAL, A RANDOMIZED ADAPTIVE PLATFORM TRIAL FOR NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA
Neuro-Oncology2024-11-011 citations
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
2023-11-1814 citations
CTNI-17. APPLICATION OF THE GBM-X DATA PLATFORM TO ESTIMATE TREATMENT EFFECTS OF THE EXPERIMENTAL THERAPIES OF THE RANDOMIZED PHASE 2 INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPIES
Neuro-Oncology2023-11-01
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization
Journal of Clinical Oncology2023-09-1838 citations
Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system
Neuro-Oncology Advances2023-01-0117 citations
Feasibility and conduct of INSIGhT, a platform trial of patients with glioblastoma using Bayesian adaptive randomization.
Journal of Clinical Oncology2022-06-012 citations
Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II platform trial using Bayesian adaptive randomization.
Journal of Clinical Oncology2021-05-2018 citations
Evaluating the benefit of adaptive randomization in the CC-115 arm of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II randomized Bayesian adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma.
Journal of Clinical Oncology2021-05-207 citations
<p>First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy</p>
Cancer Management and Research2019-12-0179 citations
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma
JCO Precision Oncology2019-03-2775 citations
INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA
Neuro-Oncology2018-11-01
c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study.
Journal of Clinical Oncology2018-05-204 citations
ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.
Journal of Clinical Oncology2018-05-201 citations
Individualized screening trial of innovative glioblastoma therapy (INSIGhT).
Journal of Clinical Oncology2017-05-2016 citations
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia
Blood2016-05-2869 citations
Phase I trial of a dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers.
Journal of Clinical Oncology2016-05-2020 citations
Abstract 3624: A novel, selective DNA-PK inhibitor sensitizes poor prognosis chronic lymphocytic leukemia (CLL) cells to mitoxantrone
Cancer Research2015-08-01